Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLH versus TCH neoadjuvant therapy for HER2-positive breast cancer
ChiCTR1800020175Phase 3Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Jan 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, lobaplatin, trastuzumab and carboplatin in breast cancer (2 arms), sponsored by Southwest Hospital of Army Medical University. Primary endpoints: pathologic complete response, overall survival and 1 more. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1800020175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020175.